The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Apple CEO Gets Hotly Debated Liver Transplant

Back to News Homepage

Next

HCV Research and Development Company a Promising Investment

Trial Tackling Hepatitis C With New Drug

June 30, 2009

Print this page

By enrolling Hepatitis C patients for whom treatment with combination therapy is not advised, Conatus Pharmaceuticals is testing a unique compound that inhibits the activity of matrix metalloproteinases.

Conatus Pharmaceuticals Initiates Second Phase-II Hepatitis Trial

24-June-2009

By Staff Reporter

CTS-1027 is an oral, small molecule compound that inhibits the activity of matrix metalloproteinases

Conatus Pharmaceuticals (Conatus) has initiated the second phase-II clinical trial with a drug candidate, for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom treatment with approved standard of care treatments is not currently advised.

CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027 had previously shown to be effective in multiple preclinical models of inflammatory liver disease and HCV infection.

The clinical trial is a double-blind, placebo-controlled trial, testing an optimized dose of CTS-1027 alone or in combination with ribavirin. Dosing will last for up to 24 weeks. The company expects approximately 70 patients to be enrolled. The clinical trial will be conducted at 25 medical centers in the US.

Results from an earlier clinical trial in HCV patients who failed standard of care treatment, are expected to be reported later this year.

URL for Article Source:
http://www.pharmaceutical-business-review.com/news/conatus_pharmaceuticals_initiates_second_phaseii_hepatitis_trial_090624

No Comments - be the first!
Share
Share

Previous

Apple CEO Gets Hotly Debated Liver Transplant

Back to News Homepage

Next

HCV Research and Development Company a Promising Investment

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.